Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions

M. H. Freedman, D. Grisaru, N. Olivieri, I. MacLusky and P. S. Thorner
Department of Pediatrics, Hospital for Sick Children, University of Toronto, Ontario, Canada.

Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload. Within 5 to 9 days of starting the infusions, four patients developed a pulmonary syndrome of moderate to life-threatening severity characterized by tachypnea, hypoxemia, and a diffuse interstitial pattern on chest roentgenogram. Pulmonary function studies showed restrictive dysfunction. Lung biopsy showed diffuse abnormalities with alveolar damage, interstitial fibrosis, and inflammation. The inflammatory infiltrate comprised lymphocytes, eosinophils, and mast cells. Exposure of the biopsy specimen to fluorescein-conjugated anti-IgE antibody showed fixation of IgE to the mast cell surface, suggesting a hypersensitivity reaction. Detailed studies failed to identify an infectious agent. The temporal relationship between drug administration and lung disease, and the clinical similarities in the four affected patients, strongly suggested a cause and effect relationship. We recommend that therapy with continuous intravenous infusions of deferoxamine be monitored carefully with respect to pulmonary status.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pulmonary function tests in children with beta-thalassemia major
Abu-Ekteish et al.
Chronic Respiratory Disease 2007;4:19-22.
ABSTRACT  

Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use
PORTER et al.
Ann. N. Y. Acad. Sci. 2005;1054:155-168.
ABSTRACT | FULL TEXT  

Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for Neuroblastoma
De Bernardi et al.
JCO 2003;21:1592-1601.
ABSTRACT | FULL TEXT  

Respiratory function in patients with thalassaemia major: relation with iron overload
Li et al.
Arch. Dis. Child. 2002;87:328-330.
ABSTRACT | FULL TEXT  

HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning
Bergeron et al.
Blood 2002;99:3019-3026.
ABSTRACT | FULL TEXT  

Deferoxamine toxicity in hepatoma and primary rat cortical brain cultures
Christensen et al.
Hum Exp Toxicol 2001;20:365-372.
ABSTRACT  

Secondary Iron Overload
Kushner et al.
ASH Education Book 2001;2001:47-61.
ABSTRACT | FULL TEXT  

Decreased Intracellular Iron Availability Suppresses Epithelial Cell Surface Plasmin Generation . Transcriptional and Post-transcriptional Effects on u-PA and PAI-1 Expression
Hasegawa et al.
Am. J. Respir. Cell Mol. Bio. 1999;21:275-282.
ABSTRACT | FULL TEXT  

Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri and Brittenham
Blood 1997;89:739-761.
FULL TEXT  

Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major
Brittenham et al.
NEJM 1994;331:567-573.
ABSTRACT | FULL TEXT